| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VACCINE.2016.02.075 |
| P698 | PubMed publication ID | 26979135 |
| P50 | author | Thomas F Wierzba | Q114998106 |
| P2093 | author name string | Richard I Walker | |
| Sachin Mani | |||
| P2860 | cites work | Enhancing Oral Vaccine Potency by Targeting Intestinal M Cells | Q21089613 |
| Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. | Q26782024 | ||
| Choice and Design of Adjuvants for Parenteral and Mucosal Vaccines | Q26783488 | ||
| Estimating diarrheal illness and deaths attributable to Shigellae and enterotoxigenic Escherichia coli among older children, adolescents, and adults in South Asia and Africa | Q27026001 | ||
| Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 | Q27860791 | ||
| Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 | Q28083357 | ||
| Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 | Q28111913 | ||
| Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1 | Q28343287 | ||
| High yield production process for Shigella outer membrane particles | Q28728768 | ||
| Pathogen-specific burdens of community diarrhoea in developing countries: a multisite birth cohort study (MAL-ED). | Q30278967 | ||
| Quantitative PCR for detection of Shigella improves ascertainment of Shigella burden in children with moderate-to-severe diarrhea in low-income countries | Q30416070 | ||
| Pathogenesis, virulence, and infective dose | Q33304216 | ||
| Virulence, inflammatory potential, and adaptive immunity induced by Shigella flexneri msbB mutants | Q33557800 | ||
| Serum bactericidal assays to evaluate typhoidal and nontyphoidal Salmonella vaccines | Q33601858 | ||
| A piglet model of acute gastroenteritis induced by Shigella dysenteriae Type 1 | Q33678906 | ||
| Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel | Q34006223 | ||
| Modulation of endotoxicity of Shigella generalized modules for membrane antigens (GMMA) by genetic lipid A modifications: relative activation of TLR4 and TLR2 pathways in different mutants | Q34138990 | ||
| Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. | Q34189195 | ||
| Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers | Q34194587 | ||
| Shigella isolates from the global enteric multicenter study inform vaccine development | Q34202171 | ||
| Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study | Q34345075 | ||
| Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes | Q34347258 | ||
| Changing emergence of Shigella sero-groups in Bangladesh: observation from four different diarrheal disease hospitals | Q34712010 | ||
| Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidates. | Q34809879 | ||
| Global causes of diarrheal disease mortality in children <5 years of age: a systematic review | Q34984052 | ||
| Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant. | Q35066293 | ||
| Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines. | Q35772614 | ||
| Broadly protective Shigella vaccine based on type III secretion apparatus proteins | Q35805439 | ||
| Molecular pathogenesis of Shigella spp.: controlling host cell signaling, invasion, and death by type III secretion. | Q36422508 | ||
| Live-attenuated Shigella vaccines | Q36689023 | ||
| Shigella's ways of manipulating the host intestinal innate and adaptive immune system: a tool box for survival? | Q36703588 | ||
| Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road | Q36844719 | ||
| Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains | Q36989057 | ||
| Establishment of a Shigella sonnei human challenge model in Thailand | Q37066116 | ||
| Progress and pitfalls in Shigella vaccine research | Q37105553 | ||
| Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli | Q37335500 | ||
| Inactivated and subunit vaccines to prevent shigellosis | Q37640115 | ||
| Immunomodulation of gut-associated lymphoid tissue: current perspectives | Q37642859 | ||
| Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine. | Q37643320 | ||
| Defending the mucosa: adjuvant and carrier formulations for mucosal immunity | Q37867814 | ||
| The Shigella human challenge model | Q38035961 | ||
| Recent progress towards development of a Shigella vaccine | Q38068954 | ||
| Outer membrane protein A (OmpA) from Shigella flexneri 2a: a promising subunit vaccine candidate | Q38114268 | ||
| An assessment of enterotoxigenic Escherichia coli and Shigella vaccine candidates for infants and children | Q38284501 | ||
| Shigella manipulates host immune responses by delivering effector proteins with specific roles | Q38497238 | ||
| Epidemiology of Shigella-associated diarrhea in rural Egyptian children. | Q38858613 | ||
| Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile | Q39252440 | ||
| Immunogenicity and efficacy of highly purified invasin complex vaccine from Shigella flexneri 2a. | Q40123700 | ||
| Introduction of Shigella flexneri 2a type and group antigen genes into oral typhoid vaccine strain Salmonella typhi Ty21a | Q40160672 | ||
| Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis | Q40211202 | ||
| Stable expression of Shigella sonnei form I O-polysaccharide genes recombineered into the chromosome of live Salmonella oral vaccine vector Ty21a | Q40255046 | ||
| Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial | Q40501431 | ||
| Production of IFN-gamma and IL-10 to Shigella invasins by mononuclear cells from volunteers orally inoculated with a Shiga toxin-deleted Shigella dysenteriae type 1 strain | Q41480678 | ||
| Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies | Q41902347 | ||
| In vivo production of a novel glycoconjugate vaccine against Shigella flexneri 2a in recombinant Escherichia coli: identification of stimulating factors for in vivo glycosylation | Q42120657 | ||
| Cross-protection provided by live Shigella mutants lacking major antigens. | Q42695434 | ||
| Synthesis of two linear PADRE conjugates bearing a deca- or pentadecasaccharide B epitope as potential synthetic vaccines against Shigella flexneri serotype 2a infection | Q45237263 | ||
| New animal model of shigellosis in the Guinea pig: its usefulness for protective efficacy studies. | Q53579124 | ||
| A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. | Q54158784 | ||
| Vaccination of children in low-resource countries against Shigella is unlikely to present an undue risk of reactive arthritis. | Q55052109 | ||
| Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. | Q64948328 | ||
| Effect of prior infection with virulent Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnei | Q67941446 | ||
| Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population | Q68134308 | ||
| Immunity in Shigellosis. II. Protection Induced by Oral Live Vaccine or Primary Infection | Q69156182 | ||
| Evaluation of Shigella vaccine safety and efficacy in an intranasally challenged mouse model | Q70573636 | ||
| Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media | Q81445405 | ||
| P433 | issue | 26 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccine | Q134808 |
| P304 | page(s) | 2887-2894 | |
| P577 | publication date | 2016-03-12 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Status of vaccine research and development for Shigella | |
| P478 | volume | 34 |
| Q91760327 | A Combined YopB and LcrV Subunit Vaccine Elicits Protective Immunity against Yersinia Infection in Adult and Infant Mice |
| Q57929967 | A Novel Proteome Microarray Discriminates Targets of Human Antibody Reactivity following Oral Vaccination and Experimental Challenge |
| Q49210830 | A Phase 2a Randomized Study to Evaluate the Safety and Immunogenicity of the 1790GAHB Generalized Modules for Membrane Antigen Vaccine against Shigella sonnei Administered Intramuscularly to Adults from a Shigellosis-Endemic Country |
| Q57170680 | A Phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against Shigella sonnei |
| Q36330258 | Bacteriophage preparation lytic for Shigella significantly reduces Shigella sonnei contamination in various foods |
| Q64114469 | Booster Vaccination With GVGH 1790GAHB GMMA Vaccine Compared to Single Vaccination in Unvaccinated Healthy European Adults: Results From a Phase 1 Clinical Trial |
| Q102329284 | Broadly reactive human CD4+ T cells against Enterobacteriaceae are found in the naïve repertoire and are clonally expanded in the memory repertoire |
| Q93167721 | Childhood diarrhoeal diseases in developing countries |
| Q92487093 | Classical and novel strategies to develop a Shigella glycoconjugate vaccine: from concept to efficacy in human |
| Q91801457 | Consensus Report on Shigella Controlled Human Infection Model: Conduct of Studies |
| Q91801443 | Consensus Report on Shigella Controlled Human Infection Model: Introduction and Overview |
| Q47795634 | Considerations for using ETEC and Shigella disease burden estimates to guide vaccine development strategy. |
| Q59138059 | Cross-Protective Whole-Cell Vaccine With a Truncated O-Polysaccharide Chain |
| Q38853686 | Detergent Isolation Stabilizes and Activates the Shigella Type III Secretion System Translocator Protein IpaC. |
| Q55385280 | Dextran-Conjugated Lysozymes Inhibit the Growth of Shigella sonnei and Viral Hemorrhagic Septicemia Virus. |
| Q58605774 | Diarrheal etiology and impact of co-infections on rotavirus vaccine efficacy estimates in a clinical trial of a monovalent human-bovine (116E) oral rotavirus vaccine, Rotavac, India |
| Q46180723 | Escherichia coli pathotypes and Shigella sero-groups in diarrheic children in Nairobi city, Kenya |
| Q99616537 | Establishment of a Controlled Human Infection Model with a Lyophilized Strain of Shigella sonnei 53G |
| Q57068847 | Evaluation of a conjugate vaccine platform against enterotoxigenic Escherichia coli (ETEC), Campylobacter jejuni and Shigella |
| Q93090016 | Extensive inter-strain diversity among clinical isolates of Shigella flexneri with reference to its serotype, virulence traits and plasmid incompatibility types, a study from south India over a 6-year period |
| Q93161233 | Freeze-dried tablets for oral vaccine delivery: Ease of administration and potential for production in existing facilities |
| Q89907757 | High Rates of Antimicrobial Resistance and Virulence Gene Distribution Among Shigella spp. Isolated from Pediatric Patients in Tehran, Iran |
| Q91069899 | Identification of Formaldehyde-Induced Modifications in Diphtheria Toxin |
| Q92261974 | Implications and measurement of herd protection (indirect effects) for enteric vaccine development |
| Q89250960 | Linalool, citral, eugenol and thymol: control of planktonic and sessile cells of Shigella flexneri |
| Q57927103 | Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990-2016 |
| Q100731064 | NAIP-NLRC4-deficient mice are susceptible to shigellosis |
| Q91705205 | Oral immunization with LacVax® OmpA induces protective immune response against Shigella flexneri 2a ATCC 12022 in a murine model |
| Q53701548 | Potential targets for next generation anti-microbial glycoconjugate vaccines. |
| Q47093864 | Preformulation studies with the Escherichia coli double mutant heat-labile toxin adjuvant for use in an oral vaccine |
| Q91583738 | Prevalence of Shigella boydii in Bangladesh: Isolation and Characterization of a Rare Phage MK-13 That Can Robustly Identify Shigellosis Caused by Shigella boydii Type 1 |
| Q90246288 | Recent Advances in the Synthesis of Glycoconjugates for Vaccine Development |
| Q91689946 | Regulated Delayed Shigella flexneri 2a O-antigen Synthesis in Live Recombinant Salmonella enterica Serovar Typhimurium Induces Comparable Levels of Protective Immune Responses with Constitutive Antigen Synthesis System |
| Q89869102 | Reverse vaccinology approach for the identification and characterization of outer membrane proteins of Shigella flexneri as potential cellular- and antibody-dependent vaccine candidates |
| Q92968346 | Role of antigen specific T and B cells in systemic and mucosal immune responses in ETEC and Shigella infections, and their potential to serve as correlates of protection in vaccine development |
| Q38665950 | Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe. |
| Q91881906 | Serum IgG antibodies to Shigella lipopolysaccharide antigens - a correlate of protection against shigellosis |
| Q37477191 | Shigella Vaccine Development: Finding the Path of Least Resistance |
| Q92968788 | Shigella-mediated immunosuppression in the human gut: subversion extends from innate to adaptive immune responses |
| Q56383780 | Shigellosis |
| Q92404815 | Synthetic carbohydrate-based vaccines: challenges and opportunities |
| Q92261985 | Technical product attributes in development of an oral enteric vaccine for infants |
| Q57058815 | Use of quantitative molecular diagnostic methods to investigate the effect of enteropathogen infections on linear growth in children in low-resource settings: longitudinal analysis of results from the MAL-ED cohort study |
| Q52625300 | Use of zebrafish to study Shigella infection. |
| Q64244950 | Vaccination With Mouse Dendritic Cells Loaded With an IpaD-IpaB Fusion Provides Protection Against Shigellosis |
| Q47722353 | WHO consultation on ETEC and Shigella burden of disease, Geneva, 6-7th April 2017: Meeting report |
| Q94553680 | Zebrafish as an alternative animal model in human and animal vaccination research |
Search more.